Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Catriona Jamieson, UCSD
Program Theme: TBA
- TBA
Speaker Profile
PMWC PIONEER AWARD
Drove checkpoint blockade into practice (incl. ipilimumab)
M.D., Ph.D., PHARMD, FAACR, FAIO, FASCO, Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
Biography
Dr. Jedd D. Wolchok is a pioneering figure in cancer immunotherapy, renowned for his instrumental role in the development and approval of groundbreaking treatments for melanoma. His leadership in clinical trials led to the FDA approval of ipilimumab, the first checkpoint inhibitor immunotherapy, and the combination of nivolumab and ipilimumab, establishing new standards of care for advanced melanoma patients. Throughout his career, Dr. Wolchok has been at the forefront of translational research, focusing on novel immunotherapeutic agents and the mechanisms of immune response to cancer. His laboratory has significantly contributed to understanding the tumor microenvironment and developing strategies to overcome resistance to immunotherapy. His contributions have been recognized with numerous prestigious awards, including the His work continues to shape the future of cancer treatment, emphasizing the potential of immunotherapy to provide durable control across various cancer types.
Talk
Clinical uses of cancer immunotherapy
We will explore innovative immunotherapeutic strategies to modulate the immune response to cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies.
Speaker Profile
Ph.D., CEO, Atropos Health
Biography
Brigham Hyde brings over 15 years experience as an Investor, Operator, and Entrepreneur in Health Tech and Data. Prior to Atropos, he was President of Data and Analytics at Eversana, a life sciences commercialization service provider. At Symphony AI he led the investment in Concert AI in the oncology RWD space and held an operating role through the first 3 years of the company.He has served as President of Data Analytics at Eversana and Chief Data Officer at DRG (exited to Clarivate 2020). He is a founder and lead investor in Atropos Health, a Stanford RWD spinout, and holds advisory positions to multiple Data and Digital health tech ventures. Before beginning his career at Cowen and Company covering Genomics and Life Science Tools, Brigham received a Ph.D. in Clinical Pharmacology from Tufts University School of Medicine. He has held research faculty positions at Tufts University and MIT Media lab.
